Late Phase II Study of TS-142 in Patients with Insomnia

Taisho Pharmaceutical Co., Ltd.1 个研究点目标入组 160 人开始时间: 待定最近更新: 2022年3月7日

试验速览

暂无简介。

•To be eligible for study participation, an individual must meet all of the following criteria:
•Japanese male and female age 20 years or older at the time of informed consent
•Outpatients
•Patients who meet the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for insomnia disorder
•Other protocol defined inclusion criteria could apply

•An individual who meets any of the following criteria will be excluded from participation
•in this study:
•Patients who meet the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria excepting insomnia disorder preceding visit 1
•Patients who meet the DSM-5 criteria for Restless legs syndrome at visit 1
•Patients with comorbid psychiatric disorder(s), including depression, schizophrenia, anxiety
•Other protocol defined exclusion criteria could apply

efficacy Sujective sleep latency (sSL)

未报告次要终点

发起方

Loading locations...